Loading video...

Video Failed to Load

Go Home

$HIMS 🚨 NEEDHAM'S RYAN MACDONALD SAYS HIS "BASE CASE" IS THAT PEPTIDES WILL BE APPROVED Jonathan Stern: "I have seen a ton of alarmist tweets saying, 'RIP to the peptide bros', essentially. And what you're saying, Ryan, is that it's really not that simple." "We have a process here....

20,461 views • 4 months ago •via X (Twitter)

8 Comments

Artur Raposo's profile picture
Artur Raposo4 months ago

Great news to us

Curo You's profile picture
Curo You4 months ago

Well we don’t have to wait much longer! Excitment is in the air

Anthony's profile picture
Anthony4 months ago

Not really sure why you'd want to be so wrong publicly. FDA rejection is a requirement with the risks inherent to these peptides. The reality is that many have lots of side effects. They pose a threat to users, prescribing clinicians and the infrastructure that supports them

Hlns Hcnsa's profile picture
Hlns Hcnsa4 months ago

My strategy plan !! 🚀 ⬇️

Hirns Haues.'s profile picture
Hirns Haues.4 months ago

Details of my stock holdings are as follows ⬇️

Daninvest23's profile picture
Daninvest234 months ago

Andrew has been quite for long.. whats your next guess?

Thoughts on Healthcare Markets and Tech's profile picture
Thoughts on Healthcare Markets and Tech4 months ago

MacDonald's base case may be right that some peptides eventually get approved through legitimate channels, but that framing skips the immediate problem: compounding pharmacies cannot legally make these substances right now under 503A, and the July PCAC meeting is building the formal evidentiary record that makes the interim enforcement gap much harder to sustain. The specific mechanism matters here. When FDA removed BPC-157, TB-500, and the other five peptides from Category 2, wellness clinic operators read that as a green light. It wasn't. Removal from Category 2 was procedural, clearing the path to formal PCAC review, and it carries no authorization to compound. The PCAC meeting is where FDA establishes on the record that these substances fail the 503A multi-factor test on chemical characterization, safety data, and human efficacy evidence simultaneously, not just one dimension. That record is what gives enforcement actions teeth going forward. The "eventual approval" thesis also quietly assumes these peptides can run the full NDA or 505(b)(2) gauntlet, which requires the kind of impurity profiling, endotoxin limits, and standardized nomenclature that most of these compounds currently lack even at the preclinical documentation level. MOTS-c was only discovered around 2015. Epitalon's evidence base is largely Russian institutional research. The clinical trial infrastructure doesn't exist yet for most of them. So the real question for Hims and the compounding ecosystem isn't whether approval is theoretically possible down the road. The question is what the liability picture looks like for the pharmacies and clinics operating during the gap between this PCAC meeting and whatever eventual regulatory clarity might arrive, and whether that gap is measured in years or... Full breakdown of the 503A mechanism and all seven peptides under review:

GrossMargin's profile picture
GrossMargin4 months ago

@grok what peptides? And why would FDA approve something that has no human randomized clinical trials behind them?

Related Videos